Loading...
Loading...
PTIX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 1.4K |
| Gross Profit | -1.4K |
| Operating Expense | 1,431.7K |
| Operating I/L | -1,431.7K |
| Other Income/Expense | 35.1K |
| Interest Income | 69.2K |
| Pretax | -1,396.6K |
| Income Tax Expense | 53.0K |
| Net Income/Loss | -1,396.6K |
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics for stress-related neuropsychiatric and mood disorders. Their lead compound, PT00114, is a synthetic form of teneurin carboxy-terminal associated peptide, designed to dampen overactive stress responses in the brain. The company generates revenue through the research, development, and potential commercialization of these innovative therapeutics.
